market-trends is the sole category represented across all 1 tracked stories. DCAT is most often covered alongside Bristol Myers Squibb, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 4.1 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about DCAT
market-trends is the sole category represented across all 1 tracked stories. DCAT is most often covered alongside Bristol Myers Squibb, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 4.1 for the same window. The 5 average consequence score is below the beat benchmark of 6 in the same window. We currently track 1 Healthcare story that mention DCAT, all published on March 9, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering DCAT. Shared-story counts are live from our verified record — not editorial picks.
LOTTE Biologics is attending DCAT Week 2026 in New York to secure high-value global partnerships and solidify its position in the CDMO market. This move underscores the company's aggressive strategy to leverage its U.S. manufacturing footprint and upcoming South Korean capacity.